Cipla Q2 Results: Revlimid competition may weigh on US sales, margin guidance awaited

Motilal Oswal expects Cipla’s US sales to fall 12% from last year to $220 million, while Kotak estimates sales to decline 3% sequentially to $220 million. For the June quarter, Cipla had reported US sales of $226 million.

Leave a Reply

Your email address will not be published. Required fields are marked *